• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.11% Nasdaq Up0.01%

    Cyclacel Pharmaceuticals, Inc. (CYCC)

    0.71 Up 0.09(14.58%) 3:59PM EST
    ProfileGet Profile for:
    Cyclacel Pharmaceuticals, Inc.
    200 Connell Drive
    Suite 1500
    Berkeley Heights, NJ 07922
    United States - Map
    Phone: 908-517-7330
    Fax: 866-271-3466
    Website: http://www.cyclacel.com

    Index Membership:N/A
    Full Time Employees:18

    Business Summary 

    Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue for the treatment of hematological cancers and solid tumors; and seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2, -7 and -9, which are central to the process of cell division and cell cycle control. Its oncology development programs also comprise CYC065, an orally-available 2nd generation CDK-2, -5, and -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer; and Aurora kinase inhibitors, a serine/threonine protein kinases that focuses on cell division, or mitosis for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cyclacel Pharmaceuticals, Inc.

    Key Executives 
    Mr. Spiro George Rombotis , 56
    Chief Exec. Officer, Pres and Exec. Director
    Mr. Paul McBarron , 54
    Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. & Admin., Sec. and Exec. Director
    Dr. Judy H. Chiao M.D., 55
    Chief Medical Officer and VP of Clinical Devel. & Regulatory Affairs
    Prof. David Glover Ph.D., FRS FRSE, 67
    Chief Scientist
    Dr. Susan Davis Ph.D.,
    Director of Bus. Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders